Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (cGMP) quality control. Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients. Source
No articles found.
GenMark Diagnostics (NASDAQ: GNMK) is a leading provider of multiplex molecular di...
GenMark Diagnostics (NASDAQ: GNMK) is a leading...
Atreca is a biotechnology company developing novel therapeutics drawn from human i...
Atreca is a biotechnology company developing no...
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developi...
Eloxx Pharmaceuticals, Inc. is a clinical-stage...
We make affordable assistive products, starting with a groundbreaking supportive w...
We make affordable assistive products, starting...
Aeglea a clinical-stage biotechnology company that engineers next generation human...
Aeglea a clinical-stage biotechnology company t...
Nemaura Medical (NASDAQ:NMRD) is a medical technology company which has developed ...
Nemaura Medical (NASDAQ:NMRD) is a medical tech...
Genprex Inc is a U.S.-based clinical-stage gene therapy company. It is engaged in ...
Genprex Inc is a U.S.-based clinical-stage gene...
Join the National Investor Network and get the latest information with your interests in mind.